6.3
肾上腺素能受体：ɑ 亚型
肾上腺素能受体基于它们对儿茶酚胺激动剂的效力被分为α 和β类。ꞵ-肾上腺素能受体的儿茶酚效力按照以下顺序排列：
肾上腺素 ≥ 去甲肾上腺素 >> 异丙肾上腺素
α-肾上腺素能受体进一步分为α1和α2亚型。
α1-肾上腺素能受体：这些受体位于效应器官的神经元后，并通过磷脂酶C—-肌醇-1,4,5-三磷…
ɑ-肾上腺素受体对肾上腺素和去甲肾上腺素的亲和力高于异丙肾上腺素。
根据多种因素，它们被分为ɑ1和ɑ2亚型。
刺激后，ɑ1受体激活磷脂酶C，释放IP3和DAG作为第二信使。
它们存在于突触后效应器官中，尤其是心血管系统和胃肠道系统的平滑肌中，负责介导血管收缩、血压升高以及胃肠道平滑肌的松弛。
ɑ2 受体激动可抑制腺苷酸环化酶，减少cAMP生成，并调节离子通道。
它们主要存在于自主神经末梢、胰腺β 细胞、血管平滑肌和血小板中。它们可影响自主神经递质和胰岛素的释放、血管平滑肌收缩以及血小板聚集。
ɑ1 和 ɑ2 受体根据亚型选择性药物进一步分为三种亚型。例如，用于治疗前列腺增生的坦索罗辛（tamsulosin）优先抑制前列腺中的 ɑ1-A 受体，而非血管中的 ɑ1-B 受体，因此其心血管系统副作用较少。
View the full transcript and gain access to JoVE Core videos
Q1: What is the difference between α1 and α2 adrenergic receptors?
α1 receptors are located postsynaptically on effector organs and activate phospholipase C, releasing IP3 and DAG as secondary messengers, causing vasoconstriction and increased blood pressure. α2 receptors are predominantly presynaptic on nerve terminals and pancreatic beta cells, inhibiting adenylyl cyclase to decrease cAMP production, modulating neurotransmitter release and insulin secretion.
Q2: How do α1 receptors affect smooth muscle in the cardiovascular and GI systems?
α1 receptor stimulation activates the phospholipase C pathway, releasing IP3 and DAG as secondary messengers. In cardiovascular smooth muscle, this causes vasoconstriction and increased blood pressure. In GI smooth muscle, α1 activation leads to muscle relaxation, reducing GI motility and contractions.
Q3: What are the main locations and functions of α2 adrenergic receptors?
α2 receptors are predominantly located on autonomic nerve terminals, pancreatic beta cells, vascular smooth muscles, and platelets. Upon stimulation, they inhibit adenylyl cyclase and decrease cAMP production, modulating the release of autonomic neurotransmitters and insulin, controlling vascular smooth muscle contraction, and affecting platelet aggregation.
Q4: Why does tamsulosin have fewer cardiovascular side effects than other α-blockers?
Tamsulosin preferentially inhibits α1-A receptors in the prostate gland over α1-B receptors in blood vessels. This receptor subtype selectivity allows the drug to treat prostatic hyperplasia effectively while minimizing cardiovascular effects like hypotension that occur when α1-B receptors in blood vessels are blocked.
Q5: How do α1 and α2 receptors differ in their catecholamine potency?
Both α1 and α2 receptors show higher affinity for adrenaline and noradrenaline than isoprenaline. However, α1 receptors are classified based on their postsynaptic location and phospholipase C activation, while α2 receptors are classified by their presynaptic location and adenylyl cyclase inhibition, reflecting distinct functional roles in the autonomic nervous system.
Q6: What are the three subtypes of α1 and α2 receptors?
α1 receptors are subdivided into α1-A, α1-B, and α1-D subtypes, while α2 receptors are subdivided into α2-A, α2-B, and α2-C subtypes. These subdivisions are based on subtype-selective drugs and their differential tissue distribution, allowing for more precise pharmacological targeting and understanding of drug-receptor selectivity.
Q7: How does α2 receptor stimulation affect ion channels and cAMP levels?
α2 receptor activation inhibits adenylyl cyclase, decreasing intracellular cAMP production and causing closure of ion channels. This mechanism contrasts with α1 receptors, which activate phospholipase C. The reduced cAMP and ion channel closure modulate autonomic neurotransmitter release and regulate vascular smooth muscle and platelet function.